Evidence map›Paper›PMID 36038232›Full record

ArticleAnalytica chimica acta2022

Platinum nanoparticles (PtNPs)-based CRISPR/Cas12a platform for detection of nucleic acid and protein in clinical samples.

Jiajie Liang, Peijun Teng, Liangshan Hu, Guanbo He, Qifang Song, Ying Zhang, Bin Peng, Gan Li, Wei Xiao, Donglin Cao and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Analytica chimica acta, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jiajie LiangGuangdong Province Engineering Research Center of Antibody Drug and Immunoassay, Department of Bioengineering, College of Life Science and Technology, Jinan University, Guangzhou, 510632, China; Department of Oncology, The First Affiliated Hospital, Jinan University, Guangzhou, 510632, China; Guangdong Biowings Tech Limited, Foshan, 528000, China.
Peijun TengGuangdong Province Engineering Research Center of Antibody Drug and Immunoassay, Department of Bioengineering, College of Life Science and Technology, Jinan University, Guangzhou, 510632, China.
Liangshan HuDepartment of Laboratory Medicine, Guangdong Second Provincial General Hospital, Guangzhou, 510317, China.
Guanbo HeGuangdong Biowings Tech Limited, Foshan, 528000, China.
Qifang SongGuangdong Province Engineering Research Center of Antibody Drug and Immunoassay, Department of Bioengineering, College of Life Science and Technology, Jinan University, Guangzhou, 510632, China.
Ying ZhangGuangdong Province Engineering Research Center of Antibody Drug and Immunoassay, Department of Bioengineering, College of Life Science and Technology, Jinan University, Guangzhou, 510632, China.
Bin PengGuangdong Province Engineering Research Center of Antibody Drug and Immunoassay, Department of Bioengineering, College of Life Science and Technology, Jinan University, Guangzhou, 510632, China.
Gan LiGuangdong Province Engineering Research Center of Antibody Drug and Immunoassay, Department of Bioengineering, College of Life Science and Technology, Jinan University, Guangzhou, 510632, China.
Wei XiaoDepartment of Laboratory Medicine, Guangdong Second Provincial General Hospital, Guangzhou, 510317, China. Electronic address: xkevent@foxmail.com.
Donglin CaoDepartment of Laboratory Medicine, Guangdong Second Provincial General Hospital, Guangzhou, 510317, China. Electronic address: caodl@126.com.
Yong TangGuangdong Province Engineering Research Center of Antibody Drug and Immunoassay, Department of Bioengineering, College of Life Science and Technology, Jinan University, Guangzhou, 510632, China. Electronic address: tyjaq7926@163.com.
Jinan University · CNGuangdong Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early rapid screening diagnostic assay is essential for the identification, prevention, and evaluation of many contagious or refractory diseases. The optical density transducer created by platinum nanoparticles (PtNPs) (OD-CRISPR) is reported in the present research as a cheap and easy-to-execute CRISPR/Cas12a-based diagnostic platform. The OD-CRISPR uses PtNPs, with ultra-high peroxidase-mimicking activity, to increase the detection sensitivity, thereby enabling the reduction of detection time and cost. The OD-CRISPR can be utilized to identify nucleic acid or protein biomarkers within an incubation time of 30-40min in clinical specimens. In the case of taking severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) N gene as an instance, when compared to a quantitative reverse transcription-polymerase chain reaction (RT-qPCR), the OD-CRISPR test attains a sensitivity of 79.17% and a specificity of 100%. In terms of detecting prostate-specific antigen (PSA), aptamer-based OD-CRISPR assay achieves the least discoverable concentration of 0.01 ng mL

Indexed as

COVID-19Metal NanoparticlesNucleic AcidsCRISPR-Cas SystemsHumansNucleic Acid Amplification TechniquesPlatinumSARS-CoV-2Nucleic AcidsPlatinumBiosensorCRISPR/Cas12aNoble metal nanocatalystsNucleic acid detectionProtein detectionSARS-CoV-2

Identifiers

PMID36038232
PMCPMC9365833
OpenAlexW4292330639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.